Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.

Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S.

Cancer Res. 2010 Oct 1;70(19):7580-90. doi: 10.1158/0008-5472.CAN-10-0436. Epub 2010 Sep 14.

2.

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S.

Mol Cancer. 2010 May 26;9:121. doi: 10.1186/1476-4598-9-121.

3.

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Sierra JR, Cepero V, Giordano S.

Mol Cancer. 2010 Apr 12;9:75. doi: 10.1186/1476-4598-9-75.

4.

Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.

Cepero V, Sierra JR, Giordano S.

Curr Pharm Des. 2010;16(12):1396-409. Review.

PMID:
20166985
5.

Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages.

Sierra JR, Corso S, Caione L, Cepero V, Conrotto P, Cignetti A, Piacibello W, Kumanogoh A, Kikutani H, Comoglio PM, Tamagnone L, Giordano S.

J Exp Med. 2008 Jul 7;205(7):1673-85. doi: 10.1084/jem.20072602. Epub 2008 Jun 16.

6.

Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.

Cepero V, García-Serrelde B, Moneo V, Blanco F, González-Vadillo AM, Alvarez-Valdés A, Navarro-Ranninger C, Carnero A.

Clin Transl Oncol. 2007 Aug;9(8):521-30.

PMID:
17720655

Supplemental Content

Loading ...
Support Center